Why did compounded GLP-1s become so common?

During FDA-declared shortages of brand-name semaglutide and tirzepatide, federal rules temporarily allowed compounding pharmacies to produce versions of these drugs to meet demand that manufacturers couldn't fill. For many patients — particularly those without insurance coverage or facing high out-of-pocket costs — compounded versions became a genuine access lifeline.

What happens to compounding now that the shortages have ended?

Once official shortages are declared resolved, compounding is generally required to stop for a resolved-shortage drug. That requirement is what has generated much of the current tension, since the underlying affordability problem that drove patients to compounded versions hasn't gone away.

Is one side of this debate simply right?

Both concerns are grounded in real evidence: cost genuinely blocks access for many patients, and quality control genuinely varies in compounded products, particularly from illegitimate sources. The most constructive advocacy positions tend to focus on specific asks — stronger enforcement against grey-market sellers, transparent quality standards for legitimate compounders, and improved coverage and lower prices that would reduce reliance on compounding in the first place.

What should I check if I use or have used compounded GLP-1 medication?

Whether your source is a licensed, quality-standard-compliant compounding pharmacy versus an unregulated grey-market seller is a meaningful safety distinction. Beyond individual sourcing decisions, advocacy in this space is most effective when directed at the root causes — affordability and supply — rather than treating compounding access itself as the end goal.

The compounding pharmacy debate: patient access vs. safety regulation

When brand-name GLP-1 supply couldn't meet demand, compounded versions filled the gap for many patients who couldn't otherwise afford or access treatment. Here's the tension between access and safety at the center of that debate.

Updated Jul 18, 2026

How the debate started

During periods of FDA-declared shortage of brand-name semaglutide and tirzepatide, federal rules temporarily allowed compounding pharmacies to produce versions of these drugs to meet patient demand that manufacturers couldn't fill. For many patients — particularly those without insurance coverage or facing high out-of-pocket costs for brand-name products — compounded versions became a genuine access lifeline. Once official shortages are declared resolved, compounding is generally required to stop for a resolved-shortage drug, which has generated real tension.

The access argument

Advocates for continued compounding access point to the significant cost gap between brand-name and compounded products, arguing that restricting compounding without addressing underlying affordability effectively cuts off treatment access for patients who can't afford brand-name pricing or lack sufficient insurance coverage — disproportionately affecting the same populations covered in our guide on access disparities.

The safety argument

Manufacturers and the FDA have raised concerns about compounded GLP-1 products specifically: inconsistent dosing accuracy, product purity, and the rise of the unregulated grey market operating adjacent to (and sometimes indistinguishable from, to patients) legitimate licensed compounding. Adverse event reports tied to dosing errors in compounded products have been part of the regulatory rationale for tightening rules once shortages resolve.

Why this isn't a simple either/or

Both concerns are grounded in real evidence: cost genuinely blocks access for many patients, and quality control genuinely varies in compounded products, particularly from illegitimate or unlicensed sources. The most constructive advocacy positions in this debate tend to focus not on "compounding good/bad" broadly, but on specific asks: stronger enforcement against illegitimate grey-market sellers, transparent standards for legitimate compounders, and — the underlying driver of the whole debate — improved insurance coverage and lower list prices that would reduce reliance on compounding as a cost workaround in the first place.

compoundingaccesssafetyadvocacy

Was this helpful?

Common questions

Questions people often ask about this topic.

Why did compounded GLP-1s become so common?
During FDA-declared shortages of brand-name semaglutide and tirzepatide, federal rules temporarily allowed compounding pharmacies to produce versions of these drugs to meet demand that manufacturers couldn't fill. For many patients — particularly those without insurance coverage or facing high out-of-pocket costs — compounded versions became a genuine access lifeline.
What happens to compounding now that the shortages have ended?
Once official shortages are declared resolved, compounding is generally required to stop for a resolved-shortage drug. That requirement is what has generated much of the current tension, since the underlying affordability problem that drove patients to compounded versions hasn't gone away.
What are the safety concerns with compounded GLP-1s?
Manufacturers and the FDA have raised concerns about inconsistent dosing accuracy and product purity, along with the rise of an unregulated grey market operating adjacent to — and sometimes indistinguishable from, to patients — legitimate licensed compounding. Adverse event reports tied to dosing errors in compounded products have been part of the regulatory rationale for tightening rules.
Is one side of this debate simply right?
Both concerns are grounded in real evidence: cost genuinely blocks access for many patients, and quality control genuinely varies in compounded products, particularly from illegitimate sources. The most constructive advocacy positions tend to focus on specific asks — stronger enforcement against grey-market sellers, transparent quality standards for legitimate compounders, and improved coverage and lower prices that would reduce reliance on compounding in the first place.

Improve this page